The current management team includes:  

Nicolas Druz, Chief Executive Officer, Chairman of the Board

Mr. Nicolas Druz joined Pharmagenesis, Inc. in 1993 as advisor to the Chairman, and became a member of the Board in 1995.  He was appointed CEO in 1996 by Pharmagenesis' founder, Mr. Tih-Wu Wang, and led the company during its successful development of PG2, TriptoSar and WilGraf.  In 2003, Mr. Druz became Executive Chairman of Pharmagenesis, Inc.  Mr. Druz is also President and CEO of Europe Journal, President of Jeanne Lanvin SA, President and CEO of Euro Pacific Communication, Board member of Société des Papiers de Presse.  He represents the private interests of the Wang family in various institutions, like W.B.A., Inc., a hotel company located in Paris.  Mr. Druz is Managing Director of Harmonie SA, Vice Chairman of Tianjin Hualong Pharmaceutical, Board Member of PhytoHealth, and Director of EcoPharm limited.


John H. Musser, Ph.D., Chief Operating Officer

Before joining Pharmagenesis, Inc. in 1995, Dr. Musser was Vice President of Chemistry and a Corporate Officer at Glycomed.  There he built and led Chemical R&D with a focus on carbohydrates.  Product candidates included ilomastat, a matrix metalloproteinase inhibitor to treat ocular ulceration which reached Phase III clinical trials, astenose, a heparin derivative to treat restenosis following balloon angioplasty with an IND filed in 1994, and celadin, a pre-IND sialyl Lewis X analog to treat sepsis.  An IPO was filed in 1991 employing Montgomery Securities.  Corporate collaborations included Eli Lilly, Genentech and Sankyo.  Glycomed merged with Ligand Pharmaceutical in 1995.  From 1982 to 1991, Dr. Musser was at Wyeth first as Manager than as Director of Medicinal Chemistry.  His department initiated the rapamycin immune suppression chemical research program.  Rapamycin (sirolimus, Rapamune® ) is now a product used to treat renal transplant rejection.  Also during this time, he was an inventor of Wy-50295 and ritolukast both anti-asthma agents which reached IND status.  From 1978-1982, Dr Musser was a Group Leader at USV Pharmaceutical Corporation, (currently Aventis via Rhône Poulenc Rorer).  There he discovered quazolast, and RHC5901 both of which entered clinical trials.  Dr. Musser started his career at the Upjohn Company after receiving a Doctor of Philosophy degree in Chemistry at the University of California, Santa Cruz in 1976.  He served on 3 Editorial Advisory Boards, authored 68 publications and invented 87 US patents.


John M. Fidler, Ph.D., Vice President, Biology

Dr. Fidler joined Pharmagenesis, Inc. in 1993 as Principal Scientist, then served as Senior Research Fellow before his current position.  He directed the Pharmacology effort in immunosuppression and cancer, providing IND-enabling efficacy studies for PG490-88 in cancer and coordinating pharm/tox/PK efforts.  From 1988 to 1992, Dr. Fidler was Scientist and then Senior Scientist at Cetus/Chiron, where he was Group Leader in Preclinical Studies in Autoimmunity and directed enabling efficacy and tox/PK studies for preparation of an IND in Graft-vs.-host disease.  Prior to that, Dr. Fidler established and directed the Cellular and Molecular Immunoregulation Research Group at Lederle Labs (now Wyeth) to develop and conduct in vitro and whole animal assays for immunoregulatory drug activities.  He led the characterization of the cellular mechanism of mitoxantrone immunoregulatory activity.  Dr. Fidler was an Assistant Member of the Immunpathology Dept. of the Scripps Research Institute, La Jolla, CA, from 1976-1982, after conducting post-doctoral research at The Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia.  Dr. Fidler received his B.A. with Biology Departmental Honors from The Johns Hopkins University and his Ph.D. in Immunology from Purdue University.   


Jinhua An, Ph.D., DVM, Chief Representative - China

Dr. An joined Pharmagenesis in 1994 and continuously rose in responsibility to his current position.  He directed the PG2 chemistry research and development efforts in China that resulted in a successful NDA in 2001.  Also, Dr. An has assumed all PG490 supply responsibility in China.  Recently, he was appointed Vice President of Technology at our Tianjin Hualong Pharmaceutical JV.  From 1991-1994, he was a Postdoctoral Research Associate at the Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, working with Professors Peter Albersheim and Alan Darvill.  While there, he collaborated with a number of pharmaceutical companies on carbohydrate-based new drug development, and also conducted research on complex polysaccharide structure identification.  From 1985-1990, he was a Research Assistant at the Department of Biochemistry, Oklahoma State University, Stillwater, Oklahoma, under the supervision of Professor Andrew Mort.  There, he did research on purification, derivatization, and structural characterization of oligo- and polysaccharides from plant cell walls.  In 1990, Dr. An received a Ph.D. in Biochemistry form Oklahoma State University, Stillwater, Oklahoma and in 1983 he earned a DVM degree in Veterinary Medicine from the Shenyang Agricultural University, Shenyang, China.


SAB ] Milestones ] Business Dev ] Press Releases ]

[ Management ] R&D ] IP ] Contact ] Site Map ]

Home ]